Table 4: Patients Shifting from Normal to Abnormal (Elevated) Cholesterol Levels, and Vice Versa, from Baseline to the End of Treatment (Year 3)

Total Cholesterol
Patients on Placebo, n (%)
Year 3 Total
Normal Abnormal
Baseline Normal 6 (16.7) 3 (8.3) 9 (25.0)
Abnormal 4 (11.1) 23 (63.9) 27 (75.0)
Total 10 (27.8) 26 (72.2) 36 (100)
p=NS
Patients on CGS, n (%)
Year 3 Total
Normal Abnormal
Baseline Normal 12 (19.4) 7 (11.3) 19 (30.6)
Abnormal 9 (14.5) 34 (54.8) 43 (69.4)
Total 21 (33.9) 41 (66.1) 62 (100)
p=NS
LDL Cholesterol
Patients on placebo, n (%)
Year 3 Total
Normal Abnormal
Baseline Normal 8 (22.2) 4 (11.1) 12 (33.3)
Abnormal 5 (13.9) 19 (52.8) 24 (66.7)
Total 13 (36.1) 23 (63.9) 36 (100)
p=NS
Patients on CGS, n (%)
Year 3 Total
Normal Abnormal
Baseline Normal 7 (11.1) 5 (7.9) 12 (19.0)
Abnormal 9 (14.3) 42 (66.7) 51 (81.0)
Total 16 (25.4) 47 (74.6) 63 (100)
p=NS

This analysis takes into account patients for whom both values (baseline and 3-year) were available.NS=not significant by McNemar test.CGS=crystalline glucosamine sulfate.